Company Analysis Nektar Therapeutics
1. Summary
Advantages
- Price (0.82 $) is less than fair price (0.9351 $)
- The stock's return over the last year (-4.65%) is higher than the sector average (-22.93%).
Disadvantages
- Dividends (0%) are below the sector average (0.5448%).
- Current debt level 57.88% has increased over 5 years from 20.4%.
- The company's current efficiency (ROE=-210.75%) is lower than the sector average (ROE=9.69%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Nektar Therapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.8% | -20% | 2% |
| 90 days | -18% | -23.9% | -9.8% |
| 1 year | -4.7% | -22.9% | 10.1% |
NKTR vs Sector: Nektar Therapeutics has outperformed the "Healthcare" sector by 18.28% over the past year.
NKTR vs Market: Nektar Therapeutics has significantly underperformed the market by -14.78% over the past year.
Stable price: NKTR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NKTR with weekly volatility of -0.0894% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.82 $) is lower than the fair price (0.9351 $).
Price not significantly lower than the fair price: The current price (0.82 $) is slightly lower than the fair price by 14%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.21).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.7398) is lower than that of the sector as a whole (4.65).
P/BV vs Market: The company's P/BV (0.7398) is lower than that of the market as a whole (3.42).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.08) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (1.08) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.37) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.37) is lower than that of the market as a whole (25.23).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -7.58% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-7.58%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).
5.4. ROE
ROE vs Sector: The company's ROE (-210.75%) is lower than that of the sector as a whole (9.69%).
ROE vs Market: The company's ROE (-210.75%) is lower than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (-69.36%) is lower than that of the sector as a whole (0.2896%).
ROA vs Market: The company's ROA (-69.36%) is lower than that of the market as a whole (6.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-49.32%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-49.32%) is lower than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5448%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 119.49% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 19.02.2025 | ROBIN HOWARD W President & CEO |
Sale | 1.01 | 24 012 | 23 774 |
| 19.02.2025 | Wilson Mark Andrew Chief Legal Officer |
Sale | 1.01 | 11 150 | 11 040 |
| 19.02.2025 | Zalevsky Jonathan Chief R&D Officer |
Sale | 1.01 | 10 403 | 10 300 |
| 19.02.2025 | Zalevsky Jonathan Officer |
Purchase | 1.01 | 10 403 | 10 300 |
| 19.02.2025 | ROBIN HOWARD W Officer |
Purchase | 1.01 | 24 012 | 23 774 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
